Leap Therapeutics, Inc. (LPTX) News

Leap Therapeutics, Inc. (LPTX): $2.66

0.12 (-4.32%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add LPTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#199 of 365

in industry

Filter LPTX News Items

LPTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LPTX News Highlights

  • For LPTX, its 30 day story count is now at 2.
  • Over the past 20 days, the trend for LPTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest LPTX News From Around the Web

Below are the latest news stories about LEAP THERAPEUTICS INC that investors may wish to consider to help them evaluate LPTX as an investment opportunity.

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer

Yahoo | December 11, 2023

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York, NY.

Yahoo | November 21, 2023

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2023.

Yahoo | November 13, 2023

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ...

Yahoo | October 24, 2023

These 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says Baird

In the classic tune by Kenny Rogers, ‘The Gambler,’ he sang, ‘Every hand’s a winner and every hand’s a loser…’ These words hold valuable wisdom that should resonate with every investor. Regardless of your chosen investment strategy, achieving success in the stock market ultimately hinges on mastering the art of balancing risk and reward. Few segments of the stock market offer a higher potential return for the risk involved than the penny stocks, those equities priced at $5 or less. These are sto

Yahoo | October 3, 2023

Leap Therapeutics to Participate at Upcoming Investor Conferences

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in two upcoming investor conferences:

Yahoo | September 5, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Investors will want to get ready for another busy day of trading as we cover the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | August 16, 2023

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for second quarter ended June 30, 2023.

Yahoo | August 14, 2023

10 Most Promising Penny Stocks According to Analysts

In this article, we will take a look at the 10 most promising penny stocks according to analysts. To see more such companies, go directly to 5 Most Promising Penny Stocks According to Analysts. Innovation is what drives human societies forward. Major companies of today were once small companies working on innovative and disruptive ideas. […]

Yahoo | August 13, 2023

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal cancer (CRC) in its DeFianCe study, it has initiated the 130 patient randomized controlled Part B of the Phase 2 study. The study evaluates Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with standard of care bevacizumab and chemotherapy a

Yahoo | July 12, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!